SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness

In order to support vaccine development, and to aid convalescent plasma therapy, it would be important to understand the kinetics, timing and persistence of SARS-CoV-2 neutralizing antibodies (NAbs), and their association with clinical disease severity. Therefore, we used a surrogate viral neutraliz...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeewandara, Chandima, Jayathilaka, Deshni, Gomes, Laksiri, Wijewickrama, Ananda, Narangoda, Eranga, Idampitiya, Damayanthi, Guruge, Dinuka, Wijayamuni, Ruwan, Manilgama, Suranga, Ogg, Graham S., Tan, Chee Wah, Wang, Lin-Fa, Malavige, Gathsaurie Neelika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819970/
https://www.ncbi.nlm.nih.gov/pubmed/33479465
http://dx.doi.org/10.1038/s41598-021-81629-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819970/
https://www.ncbi.nlm.nih.gov/pubmed/33479465
http://dx.doi.org/10.1038/s41598-021-81629-2

Ejemplares similares